These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15645133)

  • 21. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
    Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
    Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
    Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
    Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.
    Li J; Viallet J; Haura EB
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):525-34. PubMed ID: 17505826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3.
    Ku JM; Hong SH; Kim HI; Kim MJ; Kim SK; Kim M; Choi SY; Park J; Kim HK; Kim JH; Seo HS; Shin YC; Ko SG
    Phytomedicine; 2020 Jan; 66():153109. PubMed ID: 31790894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
    Pasqualetti G; Ricciardi S; Mey V; Del Tacca M; Danesi R
    Lung Cancer; 2011 Nov; 74(2):197-205. PubMed ID: 21529991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
    Gatzemeier U; Pluzanska A; Szczesna A; Kaukel E; Roubec J; De Rosa F; Milanowski J; Karnicka-Mlodkowski H; Pesek M; Serwatowski P; Ramlau R; Janaskova T; Vansteenkiste J; Strausz J; Manikhas GM; Von Pawel J
    J Clin Oncol; 2007 Apr; 25(12):1545-52. PubMed ID: 17442998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
    Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
    Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.
    Zinner RG; Glisson BS; Fossella FV; Pisters KM; Kies MS; Lee PM; Massarelli E; Sabloff B; Fritsche HA; Ro JY; Ordonez NG; Tran HT; Yang Y; Smith TL; Mass RD; Herbst RS
    Lung Cancer; 2004 Apr; 44(1):99-110. PubMed ID: 15013588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
    Villalona-Calero MA; Ritch P; Figueroa JA; Otterson GA; Belt R; Dow E; George S; Leonardo J; McCachren S; Miller GL; Modiano M; Valdivieso M; Geary R; Oliver JW; Holmlund J
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6086-93. PubMed ID: 15447994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine, vinorelbine, and Cisplatin in the treatment of advanced nonsmall cell lung cancer.
    Hasturk S; Hatabay N; Ece F; Karatasli M; Hanta I
    Am J Clin Oncol; 2009 Jun; 32(3):280-5. PubMed ID: 19433960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
    Sandler AB; Nemunaitis J; Denham C; von Pawel J; Cormier Y; Gatzemeier U; Mattson K; Manegold C; Palmer MC; Gregor A; Nguyen B; Niyikiza C; Einhorn LH
    J Clin Oncol; 2000 Jan; 18(1):122-30. PubMed ID: 10623702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
    Georgoulias V; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Palamidas P; Vlachonikolis I;
    Lancet; 2001 May; 357(9267):1478-84. PubMed ID: 11377599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemzar platinum combinations: phase III trials in non-small cell lung cancer.
    Crinò L; Calandri C
    Lung Cancer; 2002 Nov; 38 Suppl 2():S9-12. PubMed ID: 12431823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Inhibitory effects of a combination of rmhTRAIL and gemcitabine on human non-small cell lung cancer cell line NCI-H460 cells in vitro and in vivo].
    Tang CH; Liu XQ; Yang SF; Zhu B; Gao HJ
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):808-12. PubMed ID: 19173823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer.
    Esteban E; Fra J; Sala M; Carrasco J; Corral N; Vieitez JM; Estrada E; Palacio I; Buesa JM; Lacave AJ
    Invest New Drugs; 2002 Aug; 20(3):317-26. PubMed ID: 12201494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer.
    Artal-Cortés A; Martínez-Trufero J; Herrero A; Puértolas T; Alonso V; Corral M; Ceballos C; Maurel J; Antón A
    Anticancer Drugs; 2003 Feb; 14(2):111-8. PubMed ID: 12569297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Shepherd FA; Laurie S; Gauthier I; Leighl N; Chen E; Feld R; Powers J; Seymour L
    Eur J Cancer; 2009 Mar; 45(5):782-8. PubMed ID: 19091548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
    Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
    Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
    Caffo O; Fallani S; Marangon E; Nobili S; Cassetta MI; Murgia V; Sala F; Novelli A; Mini E; Zucchetti M; Galligioni E
    Cancer Chemother Pharmacol; 2010 May; 65(6):1197-202. PubMed ID: 20140616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.